CAR-T cell therapy is named as an intervention in 5 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is The First Affiliated Hospital of Soochow University (2). The most-studied condition is B-cell Non-Hodgkin Lymphoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
NCT07344818 · ClinicalTrials.gov ↗ · R/R Aggressive B-cell Lymphoma
|
Phase EARLY_PHASE1 | Recruiting | Peking University People's Hospital | China |
|
Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
NCT07564453 · ClinicalTrials.gov ↗ · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
|
Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | China |
|
CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
NCT06567366 · ClinicalTrials.gov ↗ · Large B-cell Lymphoma
|
Phase 2 | Not yet open | Ruijin Hospital | China |
|
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
NCT03919240 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia With Failed Remission
|
Phase 1/2 | Active, closed | The First Affiliated Hospital of Soochow University | China |
|
A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
NCT06464185 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma
|
Phase 1/2 | Active, closed | Institute of Hematology & Blood Diseases Hospital, China | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| The First Affiliated Hospital of Soochow University | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Peking University People's Hospital | 1 |
| Ruijin Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 2 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name CAR-T cell therapy as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 5 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The First Affiliated Hospital of Soochow University (2), Institute of Hematology & Blood Diseases Hospital, China (1), Peking University People's Hospital (1) and Ruijin Hospital (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CAR-T cell therapy works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CAR-T cell therapy works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CAR-T cell therapy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.